IP Library Granted Patent US 8,802,920
Granted Patent B2
US 8,802,920 · App. 13/678,924 · Granted Aug 12, 2014

Acellular tissue matrices made from α-1,3-galactose-deficient tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,920
App. No.
13/678,924
Granted
Aug 12, 2014
Kind
B2
Abstract

The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.

Claims (28)

1. An acellular tissue matrix comprising:

a decellularized collagen-containing dermal tissue of a pig genetically modified to include a chromosomal genetic modification comprising a disruption of both alleles of an α-1,3 galactosyl transferase (αGT) gene such that tissues in the pig lack galactose α-1,3-galactose epitopes,

wherein the acellular tissue matrix lacks epithelial basement membrane.

2. The acellular tissue matrix of claim 1 , wherein the acellular tissue matrix is in non-particulate form.

3. The acellular tissue matrix of claim 1 , wherein the acellular tissue matrix is in particulate form.

4. A method of making an acellular tissue matrix, the method comprising:

(a) providing a collagen-containing tissue from a pig genetically modified to include a chromosomal genetic modification comprising a disruption of both alleles of an α-1,3 galactosyl transferase (αGT) gene so that tissues in the pig lack galactose α-1,3-galactose epitopes; and

(b) processing the tissue so as to render the tissue acellular and lacking an epithelial basement membrane, the processing resulting in the production of an acellular tissue matrix.

5. The method of claim 4 , further comprising freezing the acellular tissue matrix.

6. The method of claim 4 , further comprising freeze-drying the acellular tissue matrix.

7. The method of claim 4 , further comprising:

(a) pulverizing the acellular tissue matrix; or

(b) rendering the acellular tissue matrix particulate in form.

8. The method of claim 4 , wherein the process comprises removing and discarding epidermis.

9. A method of treatment, the method comprising:

(a) identifying a mammalian subject as having an organ or tissue in need of repair or amelioration; and

(b) placing a composition comprising the acellular tissue matrix of claim 1 in or on the organ or tissue.

10. The method of claim 9 wherein the subject is a human.

11. The method of claim 9 , wherein the acellular tissue matrix is in non-particulate form.

12. The method of claim 9 , wherein the acellular tissue matrix is in particulate form.

13. The method of claim 9 , further comprising administration to the subject of at least one agent selected from a cell growth factor, an angiogenic factor, a differentiation factor, a cytokine, a hormone, and a chemokine.

14. The method of claim 13 , wherein the at least one agent is in the composition placed in the subject.

15. The method of claim 13 , wherein the administration comprises injecting or infusing the at least one agent into the mammalian subject separately from the composition.

16. The method of claim 9 , wherein the organ or tissue of the subject is selected from at least one of skin, bone, cartilage, meniscus, dermis, myocardium, periosteum, artery, vein, stomach, small intestine, large intestine, diaphragm, tendon, ligament, neural tissue, striated muscle, smooth muscle, bladder, urethra, ureter, and gingiva.

17. The method of claim 9 , wherein the organ or tissue of the subject is abdominal wall fascia.

18. The method of claim 9 , wherein the composition further comprises demineralized bone powder.

19. The method of claim 16 , wherein the organ or tissue of the subject is gingiva, and wherein the gingiva is, or is proximal to, receding gingiva.

20. The method of claim 16 , wherein the organ or tissue of the subject is gingiva, and wherein the gingiva comprises a dental extraction socket.

Assignments (6)
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →